Previously, Viveve announced an exclusive distribution partnership for marketing the Viveve System with JOYMG, Co., Ltd ("JOYMG"), a leading distributor of medical devices in South Korea.
"The receipt of market approval in South Korea represents another important milestone in our commercialization of the Viveve System in Asia and our quest to make this clinically proven treatment available to the millions of women around the world who are living with vaginal laxity," said Patricia Scheller, chief executive officer of Viveve.
"South Korea represents a major global market for women's health treatments, and we expect to rapidly build our commercial presence there through our partnership with JOYMG."
Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life.
The company's lead product, the internationally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity that can result in decreased physical sensation and sexual satisfaction.
Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks.
